Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
FINANCIAL PROFILE
Novartis proposes 3.30 CHF/share¹ dividend at the AGM; 27th consecutive
dividend increase (no rebasing post Sandoz spin-off)
Financial review
4.0
CHF dividend
USD dividend4
Conclusions
3.5
2023 proposal:
CHF 3.30/USD 3.924
2022:
CHF 3.20/USD 3.514
Appendix
3.0
References
2023
1996-2023 CAGR
2.5
Dividend yield 3.9%2
Dividend growth 3.1%³
CHF: 7.2%
USD: 9.5%4
2.0
1.5
1.0 -
0.0
1996 1997 1998 1999
2000
2001 2002 2003 2004 2005
2006
2007 2008
2009 2010 2011 2012
2013
2014
2015 2016
2017 2018 2019 2020
2021 2022 2023
0.5
3. In CHF.
1. Proposal to shareholders at the 2024 Annual General Meeting, taking place on March 5, 2024. 2. Based on the NOVN closing share price of CHF 84.87, as of December 29, 2023.
4. Historical dividends per share converted at historical exchange rates at the dividend payment dates as per Bloomberg; for 2023, translated into US dollars at the FX rate of CHF/USD of 1.189, as of December 31, 2023.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
30View entire presentation